TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05669599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Maridebart Cafraglutide
Description: Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Maridebart Cafraglutide
Description: Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Maridebart Cafraglutide
Description: Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Maridebart Cafraglutide
Description: Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo by SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo by SC injection.
Study: NCT05648214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part A
Description: Administered by subcutaneous (SC) single ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part B
Description: Administered by SC parallel single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part B
Description: Administered by SC parallel single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PNP - Part B
Description: Administered by SC parallel single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (PB)
Description: Administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PB)
Description: Administered by SC injection
Study: NCT06509074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta blocker
Description: Pragmatic design. Any beta-blocker with alpha or NO activity may be used
Study: NCT05453357

Intervention type: DEVICE
Intervention: iGlucose
Description: The patient will use the monitor as instructed by their healthcare team to monitor their blood glucose.
Study: NCT04130022

Intervention type: DEVICE
Group type: OTHER
Intervention: Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.
Study: NCT04867590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endorotor
Description: The treatment itself is preceded by a sub-mucosa saline and adrenalin solution injection administered by an endoscopic sclerotherapy needle lifting the submucosa and thus reducing the risk of perforation and hemorrhage.~The interventional tool is then applied tangentially to be brought into contact with the lifted mucosa, visual monitored by endoscope. The aspiration and sectioning system is activated by use of a pedal and a generator specially made for the system, used in every procedure. The entire surface area of the targeted mucosa must be covered by the probe. The residual tissue is then removed via the aspiration system and caught by a filter. The specimens are then easily retrievable at the end of the procedure and can be stored in formalin fixing solution for histological analysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Endoscopic treatment using the HALO® 360 or 90 system is a thermal method for destroying the superficial mucosa. An initial debridement of the mucosal deposits is carried out by application of acetylcysteine in spray form with a spray catheter on the entire mucosal surface to be treated and then rinsed with water after a minute of application time.~For circumferential BEs, a single-use 360 Express® probe is used to make it possible to size the diameter of the esophagus and the treatment used. The length of the treatment area is 5 cm and several points of impact can be achieved by overlapping the catheter at two consecutive heights, with the zone spanned measuring one centimeter, in order to cover the entire pathological area requiring treatment.~For non-circumferential lesions a palette applicator is used in a variety of sizes, and in this context no sizing of the esophagus is required.
Study: NCT04932590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test
Description: The test consists in interrupting the ventilator at end-expiration for 15 seconds and assessing the resulting changes in cardiac output. Delays necessary to allow sufficient pulmonary transit time to allow good pulmonary venous return and therefore an increase in cardiac preload.
Study: NCT06154096

Intervention type: OTHER
Intervention: Acute glucagon infusion
Description: All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion

Intervention type: OTHER
Intervention: Acute glucagon infusion
Description: All subjects will undergo an amino acid infusion and pancreatic clamp during which they will have stable isotope turnover of glucose and alanine measured in two steady state periods - firstly, with low-dose glucagon infusion and secondly, with high-dose glucagon infusion
Study: NCT06626802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Dilation + Topical Mitomycin
Description: Patients with recurrent esophageal strictures in Group A will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Mitomycin applied topically at stricture site (post dilation)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Dilation + Injection Triamcinolone
Description: Patients with recurrent esophageal strictures in Group B will undergo endoscopy and balloon dilation with a CRE balloon, followed by injection Triamcinolone, injected with a sclerotherapy injector, at stricture site (post dilation)
Study: NCT06626867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Supplementation
Description: Each participant ingested either dietary fiber or placebo. The dietary fiber is indi-gestible dextrin (The WiseMan\&#39;s Dining, KING CAR OTSUKA CO., Taipei, Taiwan). The dosage of contents in each package is 6 grams, 3 packs a day, with a total dose of 18 grams.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a colored capsule with 5 grams of maltodextrin, which is taken once a day.
Study: NCT06627114

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition education program
Description: Nutritional Guidance: Emphasizing a balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats while reducing processed foods, sugars, and saturated fats.~Weight Management: Encouraging gradual weight loss if overweight, as this can significantly improve liver health.~Individualized Plans: Tailoring nutrition education to the individual needs, preferences, and any other underlying health conditions.~Monitoring and Support: Providing ongoing support and education to help participants make sustainable changes and track their progress.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acids
Description: Omega-3 Arm:1000 mg omega-3 fatty acids soft gel capsules twice daily, to be taken orally with meal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: receive routine care at the outpatient clinic. At baseline, a physician will explain the laboratory test results and the natural history of NAFLD to the patients.
Study: NCT06626841

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic floor muscles contractile capacity and activation
Description: An initial assessment of the pelvic floor is carried out when athletes arrive at the facility. Participants then complete a FFT workout, which consists of performing as many rounds as possible (AMRAP type) of 20 wallballs, 15 box jumps, and 10 burpees within 15 minutes. These plyometrics and load lifting exercises are chosen to fatigue the PFM and are simple to execute. The pelvic floor assessment is performed again at 3 minutes following the FFT workout.~Measurements of the pelvic floor parameters are conducted by a specialist physiotherapist. The muscle activation and strength of the PFM are obtained using a vaginal dynamometer (i.e. pelvimeter probe fixed at a vertex with two arms that can be separated by up to 25°), connected to the Phenix USB2, Vivaltis (Pelvimètre Phenix, Vivaltis).
Study: NCT06627946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP group
Description: Local anesthesia 0.25% bupivacine was administered in the TAP plane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP group
Description: Local anesthesia 0.25% bupivacine was administered in the TAP plane
Study: NCT04892615

Intervention type: DEVICE
Intervention: drainage tube was removed on 5th days after surgery.
Description: drainage tube was removed on 5th days after surgery.

Intervention type: DEVICE
Intervention: drainage tube was removed on 7th days after surgery.
Description: drainage tube was removed on 7th days after surgery.
Study: NCT05288972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mattress 1
Description: A mattress (M1) with the technical features suitable for scoliosis with supports the spine properly. The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mattress 2
Description: A mattress with standard technical features (M2). The mattress will use for 4 weeks, at least 5 days a week, including at least 6 hours of sleep per day.
Study: NCT05468853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the scalp targeting medial prefrontal cortex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: Transcranial magnetic stimulation delivered to the inion
Study: NCT05306574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection weekly for 52 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection weekly for 52 weeks
Study: NCT06003621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: 600mg IV every 21 days from Cycle 1 Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1,200mg IV every 21 days from Cycle 2 Day 1
Study: NCT06087328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Nicotine patch and lozenge dose
Description: 1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Nicotine patch and lozenge dose
Description: 21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Augmented Nicotine patch and lozenge dose
Description: 21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]
Study: NCT05709496

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalated radiotherapy to be delivered on the Elekta Unity Unity MR-linac
Description: 30 Gy in 5 fractions to the whole prostate with 45 Gy in 5 fractions to the dominant lesion
Study: NCT06563349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Description: Intraoperative intravenous magnesium sulfate infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Intraoperative intravenous normal saline infusion.
Study: NCT05330546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Densah burs
Description: using Densah burs to prepare implant osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ridge expansion screws
Description: using Ridge expansion screws to prepare implant osteotomy
Study: NCT05800847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be administered for 2 days at 100 mg q8h for titration to avoid side effects. The next 12 days, gabapentin will be taken at 300 mg q8h.
Study: NCT04706390

Intervention type: BIOLOGICAL
Intervention: covid-19 vaccine
Description: vaccination
Study: NCT05272813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-553
Description: MS-553
Study: NCT05345249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride Injection
Description: Investigating the effectiveness of erector spinae plane block with ropivacaine for lumbar spinal fusion surgery versus placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Placebo comparator
Study: NCT05800847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will follow the same dosing pattern as gabapentin to allow for blinding. Placebo will be encapsulated with a gelatin capsule to mimic the look of gabapentin.
Study: NCT04626245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Description: Phone-delivered brief mindfulness training based on principles of MBSR

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness training
Description: Phone-delivered brief mindfulness training based on principles of MBSR
Study: NCT05235503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal cannabis in combination with oxycodon
Description: The intervention will be administering the combination of medicinal cannabis in combination with oxycodon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medicinal cannabis in combination with placebo oxycodon
Description: The intervention will be administering the combination of medicinal cannabis in combination with placebo oxycodon
Study: NCT05314491

Intervention type: DEVICE
Intervention: Multigen Plus CCK
Description: Total Knee Arthroplasty

Intervention type: DEVICE
Intervention: Multigen Plus CCK
Description: Total Knee Arthroplasty

Intervention type: DEVICE
Intervention: AMF TT cones
Description: To fill a proximal tibia or distal femur defect
Study: NCT06516159

Intervention type: DIAGNOSTIC_TEST
Intervention: MBI-C Scale in French
Description: The original version has 34 items, divided into 5 areas:~* a reduction in motivation, interests and initiative~* the appearance of mood disorders~* dysregulation of impulse management~* loss of conventions and societal norms~* the abnormal development of strongly held beliefs and sensory experiences~The items are rated based on the occurrence of the severity of the disorders in the previous six months on a scale of 0 to 3.~This scale is completed by a member of the healthcare team on the basis of information collected from the relative (informant) either in person but also by telephone The score varies between 0 and 102. The higher the score, the more psychological and behavioral symptoms are present.~The test lasts 10 minutes.
Study: NCT05785910

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IUDS
Description: a battery of neuropsychological test
Study: NCT05165589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveInsights accelerometer device
Description: Accelerometer device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveInsights accelerometer device
Description: Accelerometer device
Study: NCT06322264

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of variation in heart rate
Description: The children will be given a portable device that will monitor their heart rate, enabling the recording of the rate of their pulse.
Study: NCT04635007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100 women: will receive preoperative 1 gram of TXA (kapron®, Amoun, Egypt) 10 minutes before skin incision, by slow intravenous injection over 10 minutes (Tranexamic acid injection will be prepared by diluting 1gm (10ml) TXA in 100 ml. of normal saline. TXA will be administrated as an intravenous infusion or slowly injection) and preoperative placebo (4 tablets similar to misoprostol in size and shape as peroxide) will be administrated rectally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 200mcg Tab
Description: 100 women: will receive preoperative 800 micrograms of misoprostol (4 tablets) rectally after spinal anesthesia and urinary catheterization (as per WHO dose recommendation) (Conde-Agudelo et al., 2013) and preoperative placebo (10 minutes before skin incision, 10 ml of distilled water ampoules by slow intravenous injection over 10 minutes).
Study: NCT06032715

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BI (Brief Intervention)
Description: Short structured individual behavioral intervention to reduce inappropriate usage of Z-hypnotics
Study: NCT05195632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Hard capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Film-coated tablet
Study: NCT05694637

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening, Brief Intervention and Referral to Treatment (SBIRT) intervention consisting of the 5As, (Ask, Advise, Assess, Assist, Arrange)
Description: Trained LHWs will oversee the screening and brief intervention procedures (i.e., the 5As). A culturally acceptable standardized form will be integrated into intake procedures within the HIV that will allow for the documentation and results of using the 5As. The first A will be the screening question where the LHW will Ask study participants about smoking. When a participant reports being a smoker, the LHW will proceed to the next 3 As (Advise, Assess, Assist). These 3As will constitute the brief intervention. The LHW will utilize motivational enhancing discussion between the study participant with a focus on increasing insight and awareness regarding smoking and motivation toward behavioral change. For those participants who are motivated for treatment, a referral will be made to a clinic nurse practitioner for evaluation for treatment with varenicline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Referral to treatment with varenicline will be provided to those identified as needing more than a brief intervention. Participants will initiate medication treatment with varenicline for smoking cessation with a quit date scheduled for day 8 following first study dose of the medication. Participants will meet with the study clinician at baseline who will provide medical clearance and sign off on prescription orders. All medication will be provided to participants by the study team. Participants will receive a weekly supply of medication for the first four weeks to ensure proper dosing and monitor for adverse events. For the subsequent 8 weeks, participants will return every 4 weeks to receive the next month's supply of medication. Dosage adjustments will be permitted in an effort to control adverse effects throughout the trial. This will allow us to balance internal validity with good clinical practice. Varenicline will be dosed in accordance with package labeling.
Study: NCT05636137

Intervention type: OTHER
Intervention: Survey application
Description: Researchers will go to the designated high schools and meet face-to-face with the responsible/guidance teachers at the school. The research will be explained to the students by going to the classrooms with the teachers, and they will be asked to fill in the consent forms of the parents and themselves. Students will be given 5 days to explain the work to their families and bring their signed consent forms. Students who bring consent forms, meet the criteria for participation in the study, and volunteer will be included in the study. Evaluation forms and questionnaires will be explained to the students included in the study by a designated researcher and they will be asked to fill them in under the supervision of the researcher. The completed evaluation form and questionnaires will be collected by a researcher in a sealed envelope.
Study: NCT05561075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pterostilbene cocrystal
Description: One capsule with Pterostilbene cocrystal